Biotech firm PepGen's Q4 net loss narrows

PepGen

04/03/2026 21:41

Overview

Biotechnology firm's Q4 net loss narrowed to $18.3 mln from $22.2 mln a year ago

Operating expenses for Q4 decreased compared to the previous year

Company is well-funded with $148.5 mln cash, sufficient for operations into 2H 2027

Outlook

PepGen expects FREEDOM2 5 mg/kg cohort data in Q1 2026

PepGen anticipates FREEDOM2 10 mg/kg cohort data in 2H 2026

Company's cash reserves expected to fund operations into 2H 2027

Result Drivers

OPERATING EXPENSES - Declined to $19.7 mln from $24.3 mln a year ago due to lower research and development expenses despite a small increase in general and administrative expenses

Company press release: ID:nBw5jwgLJa

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 EPS
-$0.27
Q4 Net Income
-$18.34 mln
Q4 Operating Expenses
$19.71 mln
Q4 Operating Income
-$19.71 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for PepGen Inc is $10.00, about 55.8% above its March 3 closing price of $6.42

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)